Related Experiment Video

Updated: Nov 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

The Next Target for NSCLC: Let It Be "RET"

Beung-Chul Ahn1, Viola W Zhu2, Sun Min Lim1

  • 1Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|November 28, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.9K

Related Experiment Videos

Last Updated: Nov 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

Articles linked to this work by shared authors, journal, and citation graph.

Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2026

A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naïve Patients with Advanced Non-small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC.

Cancer research and treatment·2026

Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Molecular epidemiology and outcomes of <i>EGFR</i> exon 20 insertion in Korean patients with non-small cell lung cancer.

Translational lung cancer research·2026

Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Weight Gain on Lorlatinib is Associated with Accumulation of Visceral Adipose Tissue.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Identifying the extra nanoparticles from SCR-equipped diesel engines and reducing them via regulating surface tension of aqueous urea solution.

Journal of hazardous materials·2026

Diverse unsaturated fatty acids bypass loss of FabH-catalysed initiation of fatty acid synthesis in <i>Enterococcus faecalis</i>.

Microbiology (Reading, England)·2026

Epigenetic remodeling during UV exposure: high resolution analysis of histone post-translational modifications in a DNA binding protein 2 mutant model.

Histochemistry and cell biology·2026

Diffusion of NiH on Ni(111) and of Ni with Adsorbed H on Ni(111) in the Context of Ni Coarsening in Solid Oxide Cells.

The journal of physical chemistry letters·2026

An Engineered Enzyme Catalyzing Tandem Reductive Aminations for Synthesizing Tertiary Amines.

Angewandte Chemie (International ed. in English)·2026

Origins of Reactivity in SAM-Utilizing Ribozyme SAMURI-Catalyzed RNA Alkylation.

Journal of the American Chemical Society·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us